蛋白酪氨酸激酶信号转导途径与抗肿瘤药物第12页,酪氨酸激酶受体的信号转导
本文关键词:蛋白酪氨酸激酶信号转导途径与抗肿瘤药物,由笔耕文化传播整理发布。
来源: 关键字: ,蛋白酪氨酸激酶信号转导途径与抗肿瘤药物
延伸:酪氨酸激酶受体的信号转导途径与肿瘤治疗
本文除了提供蛋白酪氨酸激酶信号转导途径与抗肿瘤药物 第12页的文本下载,还提供与之相关的《酪氨酸激酶受体的信号转导途径与肿瘤治疗》文本文档,希望对您有所帮助。
·334·药学学报ActaPharmaceuticaSinica2008,43(4):323-334
Inhibitionof
[34]ZhengHY,HuJD,ZhengZH,etal.Emodininduces
leukemicHL260cellsapoptosisprobablybyinhibitingAktsignalpathway[J].ActaPharmSin(药学学报),2007,42:1142-1146.
[35]BoschelliDH,WuB,YeF,etal.SynthesisandSrc
Safety,
kinaseinhibitoryactivityofaseriesof42[(2,42dichloro252methoxyphenyl)amino]272furyl232quinolinecarbonitriles[J].JMedChem,2006,49:7868-7876.
[36]GorreME,MohammedM,EllwoodK,etal.Clinical
resistancetoSTI571cancertherapycausedbyBcr2Ablgenemutationoramplification[J].Science,2001,293:876-880.
[37]SchenoneS,ManettiF,BottaM.Lastfindingsondual
inhibitorsofAblandSrc[J].MiniRevMedm,7:.
[38]M.secondgenerationc2
inhibitors
managementofgastrointestinalmors[J].ClinColorectalCancer,2006,6:30-34.
[39]JabbourE,CortesJE,GilesFJ,etal.
[J].Cancer,2007,109:2171-2181.
[40]O’SullivanLA,LiongueC,LewisRS,etal.Cytokine
TargetingtheERKsignaling
receptorsignalingthroughtheJak2Stat2Socspathwayindisease[J].MolImmunol,2007,44:2497-2506.[41]KumarS,RajeN,HideshimaT,etal.Antimyeloma
activityoftwonovelN2substitutedandtetraflourinatedthalidomideanalogs[J].Leukemia,2005,19:1253-1261.[42]BartonBE,
KarrasJG,MurphyTF,
etal.
Signal
transducerandactivatoroftranscription3(STAT3)activationinprostatecancer:directSTAT3inhibitioninducesapoptosisinprostatecancerlines[J].MolCancerTher,2004,3:11-20.
[43]BlaskovichMA,SunJ,CantorA,etal.Discoveryof
JSI2124(CucurbitacinI),aselectiveJanuskinase/signaltransducerandactivatoroftranscription3signalingpathwayinhibitorwithpotentantitumoractivityagainsthumanandmurinecancercellsinmice[J].Cancer
Mechanismsof
Res,2003,63:1270-1279.
[44]SchenoneS,BondavalliF,BottaM.
Antiangiogenic
agents:anupdateonsmallmoleculeVEGFRinhibitors[J].CurrMedChem,2007,14:2495-2516.
[45]DudaDG,JainRK,WillettCG.Antiangiogenics:the
potentialroleofintegratingthisnoveltreatmentmodalitywithchemoradiationforsolidcancers[J].JClinOncol,2007,25:4033-4042.
Currentand
emergingtreatmentoptionsinchronicmyeloidleukemia
[21]InaiT,MancusoM,HashizumeH,etal.
vascularendothelialgrowthfactor(VEGF)signalingincancercauseslossofendothelialfenestrations,regressionoftumorvessels,andappearanceofbasementmembraneghosts[J].AmJPathol,2004,165:35-52.[22]RosenLS,
KurzrockR,MulayM,
etal.
pharmacokinetics,andefficacyofAMG706,anoralmultikinaseinhibitor,inpatientswithadvancedsolidtumors[J].JClinOncol,2007,25:2369-2376.[23]WongKK.HKI2272innon2smallcelllungcancer[J].
ClinCancerRes,2007,13:4593-4596.
[24]YounesMN,YaziciYD,KimS,etal.Dualepidermal
growthfactorreceptorandvascularendothelialgrowthfactorreceptorinhibitionwithNVP2AEE788forthetreatmentofaggressivefollicularthyroidcancer[J].ClinCancerRes,2006,12:3425-3434.[25]Harousseau
173-182.
[26]ReuterCW,nV,vasculargrowthfactor(VEGF)2receptor2signalingincellcarcinoma[J].WorldJUrol,2007,25:59-72.[27]KohnoM,PouyssegurJ.
200-211.
[28]MaFY,FlancRS,TeschGH,etal.Apathogenicrole
forc2Junamino2terminalkinasesignalinginrenalfibrosisandtubularcellapoptosis[J].2007,18:472-484.
[29]VivancoI,SawyersCL.Thephosphatidylinositol32kinase
AKTpathwayinhumancancer[J].NatRevCancer,2002,2:489-501.
[30]Drugsmovingintotheclinic[EB/OL].2007:1-39.
[31]delaPenaL,BurganWE,CarterDJ,etal.Inhibitionof
Aktbythealkylphospholipidperifosinedoesnotenhancetheradiosensitivityofhumangliomacells[J].MolCancerTher,2006,5:1504-1510.[32]MacKenzieAR,
vonMehrenM.
mammaliantargetofrapamycininhibitioninsarcoma:presentandfuture[J].2007,7:1145-1154.
[33]MartelliAM,TazzariPL,EvangelistiC,etal.Targeting
thephosphatidylinositol32kinase/Akt/mammaliantargetofrapamycinmoduleforacutemyelogenousleukemiatherapy:frombenchtobedside[J].CurrMedChem,2007,14:2009-2023.
ExpertRevAnticancerTher,
JAmSocNephrol,
pathwayincancertherapy[J].AnnMed,2006,38:
JL.
Farnesyltransferase
hematologicmalignancies[J].Blood
第12页/共12页
猜您感兴趣
查看更多相关文本
编辑推荐
我也来解决
本文关键词:蛋白酪氨酸激酶信号转导途径与抗肿瘤药物,,由笔耕文化传播整理发布。
本文编号:179471
本文链接:https://www.wllwen.com/yixuelunwen/yxlw/179471.html